Holen Sie sich die Stockscreener-App
285.13
2.42%
6.73
Handel nachbörslich:
284.99
-0.14
-0.05%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$278.40
Offen:
$279.03
24-Stunden-Volumen:
1.11M
Relative Volume:
0.79
Marktkapitalisierung:
$55.26B
Einnahmen:
$316.65B
Nettoeinkommen (Verlust:
$1.90B
KGV:
29.33
EPS:
9.72
Netto-Cashflow:
$1.14B
1W Leistung:
-1.12%
1M Leistung:
-4.33%
6M Leistung:
+15.03%
1J Leistung:
+20.31%
1-Tages-Spanne:
$279.03
$285.99
1-Wochen-Bereich:
$273.43
$294.88
52-Wochen-Spanne:
$218.65
$309.35
Cencora Inc Stock (COR) Company Profile
Firmenname
Cencora Inc
Sektor
Branche
Telefon
610-727-7000
Adresse
1 WEST FIRST AVENUE, CONSHOHOCKEN
Vergleichen Sie COR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
COR
Cencora Inc
|
285.13 | 55.00B | 316.65B | 1.90B | 1.14B | 9.72 |
|
MCK
Mckesson Corporation
|
668.58 | 87.90B | 377.60B | 3.16B | 5.67B | 25.08 |
|
CAH
Cardinal Health Inc
|
157.41 | 37.38B | 222.29B | 1.56B | 2.44B | 6.41 |
|
HSIC
Henry Schein Inc
|
65.94 | 8.04B | 12.50B | 314.00M | 421.00M | 2.44 |
|
AHG
Akso Health Group Adr
|
1.71 | 654.07M | 2.22M | -5.63M | -1.68M | -0.24 |
Cencora Inc Stock (COR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-03 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-12-04 | Fortgesetzt | Mizuho | Outperform |
| 2024-09-18 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-02-26 | Eingeleitet | Leerink Partners | Outperform |
| 2024-01-03 | Eingeleitet | Barclays | Overweight |
| 2023-12-14 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-03-31 | Eingeleitet | Citigroup | Buy |
| 2023-01-31 | Fortgesetzt | Evercore ISI | Outperform |
| 2022-10-11 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-08-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-07-11 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-06-07 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2022-05-26 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2022-04-12 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-12 | Fortgesetzt | Evercore ISI | In-line |
| 2021-02-04 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2021-02-02 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-01-06 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-01-06 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-12-10 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2020-12-03 | Eingeleitet | Mizuho | Neutral |
| 2020-08-06 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-07-15 | Eingeleitet | Barclays | Underweight |
| 2020-06-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-23 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-04-16 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-04-13 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-04-01 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-03-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-02-11 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2020-02-07 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2019-09-12 | Eingeleitet | Deutsche Bank | Hold |
| 2019-07-10 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2019-04-11 | Eingeleitet | Guggenheim | Buy |
| 2019-04-10 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2019-04-10 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-02-11 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-01-17 | Eingeleitet | UBS | Buy |
| 2018-12-10 | Herabstufung | Jefferies | Buy → Hold |
| 2018-10-26 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-09-20 | Eingeleitet | Berenberg | Buy |
| 2018-07-17 | Fortgesetzt | Stifel | Hold |
| 2018-04-09 | Eingeleitet | MoffettNathanson | Buy |
| 2018-03-12 | Hochstufung | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-03-12 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2017-09-25 | Eingeleitet | JP Morgan | Neutral |
| 2017-09-22 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Cencora Inc Aktie (COR) Neueste Nachrichten
Is It Smart To Buy Cencora, Inc. (NYSE:COR) Before It Goes Ex-Dividend? - simplywall.st
Why You Might Be Interested In Cencora, Inc. (NYSE:COR) For Its Upcoming Dividend - ca.finance.yahoo.com
Published on: 2025-08-10 00:34:30 - metal.it
Cencora, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - simplywall.st
Cencora Rises 2.42% as Trading Volume Slumps to 313th Market Rank - AInvest
Cencora Q3: Growing Specialty Drug Distributions; Initiate At Buy (NYSE:COR) - Seeking Alpha
Can Specialty and GLP-1 Momentum Support Cencora's Q3 Results? - MSN
Cencora, Inc. Reports Strong Q3 2025 Financial Results - The Globe and Mail
Cencora: Fiscal Q3 Earnings Snapshot - New Haven Register
Cencora (COR) Reports Q3 Earnings Growth, Maintains US$0.55 Dividend - simplywall.st
Cencora’s Earnings Call: Strong Growth Amid Challenges - TipRanks
Cencora Earnings: Solid Results Illustrate Healthy Demand and Stable Outlook; Shares Fairly Valued - Morningstar
Cencora Says Famed GLP-1 Class Products Drive Growth, Boosts Profit Outlook - AOL.com
Cencora Benefits From Strong GLP-1 Sales, Healthy Utilization Trends, and Growing Specialty Assets - Morningstar
Cencora, Inc. SEC 10-Q Report - TradingView
Cencora raises 2025 EPS guidance to $15.85–$16 and narrows outlook as specialty drives growth - MSN
Cencora weakness after earnings ‘overdone,’ says Leerink - TipRanks
COR Q3 Earnings & Revenues Beat Estimates, '25 EPS View Raised - The Globe and Mail
Earnings call transcript: Cencora Inc. beats Q3 2025 expectations, stock dips - Investing.com Nigeria
Transcript : Cencora, Inc., Q3 2025 Earnings Call, Aug 06, 2025 - MarketScreener
Cencora (COR) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Cencora (COR) Q3 Earnings and Revenues Surpass Estimates - Yahoo Finance
Cencora Q3 2025 slides: U.S. segment drives 19.8% EPS growth, guidance raised - Investing.com Nigeria
Cencora, Inc. Exceeds Expectations with Strong Fiscal Q3 EarningsNews and Statistics - IndexBox
Cencora Inc (COR) Q3 2025 Earnings: EPS of $3.52 Beats Estimates, Revenue Hits $80.7 Billion - GuruFocus
Cencora Reports Strong Q3 2025 Financial Results - TipRanks
Cencora beats Q3 expectations, raises full-year earnings outlook By Investing.com - Investing.com Australia
Cencora, Inc. Q3 Profit Increases, Beats Estimates - Nasdaq
Cencora beats Q3 expectations, raises full-year earnings outlook - Investing.com
Cencora Inc earnings beat by $0.16, revenue topped estimates - Investing.com South Africa
Cencora Earnings Soar Past Estimates as Healthcare Giant Boosts 2025 Profit Outlook - Stock Titan
Stock Analysis | Cencora OutlookNavigating a Weak Technical Profile with Strong Fundamentals - AInvest
Cencora's $440M Volume Surge Ranks 281st Amid 0.44% Drop as Liquidity-Driven Gains Outpace Market - AInvest
Mallinckrodt Names Leslie Donato to Board of Directors - BioSpace
Cencora & The Lash Group reach $40M settlement in data breach class action - Claim Depot
What institutional investors are buying Cencora Inc. stockBuild wealth steadily with proven investment techniques - Jammu Links News
What catalysts could drive Cencora Inc. stock higher in 2025Maximize returns with disciplined trading - Jammu Links News
Should I hold or sell Cencora Inc. stock in 2025Invest in stocks with strong fundamentals - Jammu Links News
How volatile is Cencora Inc. stock compared to the marketInvest confidently with professional market insights - Jammu Links News
What are the latest earnings results for Cencora Inc.Capitalize on market shifts before others do - Jammu Links News
Cencora Inc. Stock Analysis and ForecastOutperformance with explosive growth - Jammu Links News
What makes Cencora Inc. stock price move sharplyHigh-impact investment strategies - Jammu Links News
How does Cencora Inc. compare to its industry peersCapitalize on market trends with confidence - Jammu Links News
How does Cencora Inc. generate profit in a changing economyUnlock daily market insights for better trades - Jammu Links News
How many analysts rate Cencora Inc. as a “Buy”Invest smarter with actionable stock recommendations - Jammu Links News
What analysts say about Cencora Inc. stockPhenomenal trading returns - Jammu Links News
Is it the right time to buy Cencora Inc. stockDiscover market opportunities with expert help - Jammu Links News
What markets is MKC.V expanding into Is Cencora Inc. stock a good long term investment optionBuild a portfolio that outperforms the market - Jammu Links News
What are analysts’ price targets for Cencora Inc. in the next 12 monthsHigh-profit stock alerts - Jammu Links News
What are Cencora Inc. company’s key revenue driversConsistent triple returns - Jammu Links News
What markets is Cencora Inc. expanding into Is VBTX stock a good long term investment optionAccelerated financial growth - Jammu Links News
Finanzdaten der Cencora Inc-Aktie (COR)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.61%
1.72%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):